Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy

被引:14
作者
Vaflard, Pauline [1 ]
Paoletti, Xavier [2 ,3 ,4 ]
Servois, Vincent [5 ]
Tresca, Patricia [1 ]
Pons-Tostivint, Elvire [6 ]
Sablin, Marie-Paule [1 ]
Ricci, Francesco [1 ]
Loirat, Delphine [1 ]
Hescot, Segolene [1 ]
Torossian, Nouritza [1 ]
Roufai, Diana Bello [1 ]
Kamal, Maud [1 ]
Borcoman, Edith [1 ]
Le Tourneau, Christophe [1 ,4 ,7 ]
机构
[1] Inst Curie, Dept Drug Dev & Innovat D3i, 26 Rue Ulm, F-75005 Paris, France
[2] Versailles St Quentin Univ, St Cloud, France
[3] Inst Curie, St Cloud, France
[4] INSERM, U900, Res Unit, St Cloud, France
[5] Inst Curie, Dept Radiol, Paris, France
[6] IUCT Oncopole, Dept Med Oncol, Claudius Regaud Inst, Toulouse, France
[7] Paris Saclay Univ, Paris, France
关键词
LIVER METASTASIS; CANCER; RADIOTHERAPY; RADIATION; THERAPY; PEMBROLIZUMAB; INFLAMMATION; EXPRESSION; MELANOMA; SURVIVAL;
D O I
10.1007/s40268-021-00362-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. Patients and methods Patients had to have a baseline computed tomography (CT) scan and at least one follow-up CT scan and two target lesions (TLs). Three types of DR were evaluated using RECIST1.1: DR1, defined as at least one progressive and one responding TL; DR2, defined as at least one progressive and one stable TL; and DR3, defined as at least one stable and one responding TL. Results A total of 1244 measurements of 272 TLs were performed in 100 patients. Forty-nine out of the 272 TLs (18%) had received old or recent radiotherapy, and 42 (15%) had been biopsied. An objective response was observed in 22 patients (22%) and on 52 TLs (19%). DR1 were observed in 8% of patients. At the tumor measurement level, the response rate was lower in the case of prior radiotherapy (29% vs 34%, p = 0.01) and higher in the case of prior biopsy (40% vs 32%, p = 0.02). Conclusions A DR was observed in 8% of patients. Response rate was lower in the case of prior radiotherapy and higher in the case of prior biopsy.
引用
收藏
页码:399 / 406
页数:8
相关论文
共 30 条
[1]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[2]   Novel patterns of response under immunotherapy [J].
Borcoman, E. ;
Kanjanapan, Y. ;
Champiat, S. ;
Kato, S. ;
Servois, V. ;
Kurzrock, R. ;
Goel, S. ;
Bedard, P. ;
Le Tourneau, C. .
ANNALS OF ONCOLOGY, 2019, 30 (03) :385-396
[3]   Inflammation and cancer: advances and new agents [J].
Crusz, Shanthini M. ;
Balkwill, Frances R. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (10) :584-596
[4]   Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift [J].
Formenti, Silvia C. ;
Demaria, Sandra .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (04) :256-265
[5]   Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs [J].
Gasteiger, Georg ;
Fan, Xiying ;
Dikiy, Stanislav ;
Lee, Sue Y. ;
Rudensky, Alexander Y. .
SCIENCE, 2015, 350 (6263) :981-985
[6]   Immunity, Inflammation, and Cancer [J].
Grivennikov, Sergei I. ;
Greten, Florian R. ;
Karin, Michael .
CELL, 2010, 140 (06) :883-899
[7]   Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors [J].
Grossman, Stuart A. ;
Ellsworth, Susannah ;
Campian, Jian ;
Wild, Aaron T. ;
Herman, Joseph M. ;
Laheru, Dan ;
Brock, Malcolm ;
Balmanoukian, Ani ;
Ye, Xiaobu .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (10) :1225-1231
[8]   Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer [J].
Iyengar, Puneeth ;
Kavanagh, Brian D. ;
Wardak, Zabi ;
Smith, Irma ;
Ahn, Chul ;
Gerber, David E. ;
Dowell, Jonathan ;
Hughes, Randall ;
Abdulrahman, Ramzi ;
Camidge, D. Ross ;
Gaspar, Laurie E. ;
Doebele, Robert C. ;
Bunn, Paul A. ;
Choy, Hak ;
Timmerman, Robert .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (34) :3824-U214
[9]   Canadian consensus: oligoprogressive , pseudoprogressive, and oligometastatic non-small-cell lung cancer [J].
Laurie, S. A. ;
Banerji, S. ;
Blais, N. ;
Brule, S. ;
Cheema, P. K. ;
Cheung, P. ;
Daaboul, N. ;
Hao, D. ;
Hirsh, V ;
Juergens, R. ;
Laskin, J. ;
Leighl, N. ;
MacRae, R. ;
Nicholas, G. ;
Roberge, D. ;
Rothenstein, J. ;
Stewart, D. J. ;
Tsao, M. S. .
CURRENT ONCOLOGY, 2019, 26 (01) :E81-E93
[10]   Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma [J].
Liniker, E. ;
Menzies, A. M. ;
Kong, B. Y. ;
Cooper, A. ;
Ramanujam, S. ;
Lo, S. ;
Kefford, R. F. ;
Fogarty, G. B. ;
Guminski, A. ;
Wang, T. W. ;
Carlino, M. S. ;
Hong, A. ;
Long, G. V. .
ONCOIMMUNOLOGY, 2016, 5 (09)